Talc in the news

November 6, 2026 - Attributable to Aviva Wein, Worldwide Vice President, Head of Litigation, Johnson & Johnson:

“We will immediately appeal this verdict. Without evidence to support their case, plaintiff’s attorneys relied on litigation-driven opinions that have repeatedly been disproven. In fact, decades of scientific research demonstrate Johnson’s Baby Powder does not contain asbestos and does not cause cancer. We remain confident that the evidence and the science support the safety of our products and will continue to vigorously defend these cases.” To learn more about our position and the science supporting the safety of our product, visit www.FactsAboutTalc.com.

Follows Favorable Multi-District Litigation Court Causation Ruling and the Company’s Successful Strategy to Defend Each Case Efficient Conclusion to the Talc Litigation that Eliminates Expense Associated with Litigating Remaining Roughly 76,000 Ovarian Talc Claims

January 30, 2026 - Attributable to Erik Haas, Worldwide Vice President of Litigation, Johnson & Johnson: “We applaud the trial court for its clear and decisive ruling rejecting the baseless medical monitoring claim. Plaintiff lawyers once again tried to manufacture a frivolous theory of liability, and the Court correctly refused to endorse it. This decision reinforces that meritless pleadings designed to pressure defendants into coercive settlements have no place in our courts.”

January 29, 2026 – Attributable to Erik Haas, Worldwide Vice President of Litigation, Johnson & Johnson:   “The Judge correctly rejected as wholly meritless claims contrived by the plaintiff lawyers in a failed effort to convert a proper divestiture into a fraudulent conveyance.”

Special Master erroneously allowed certain other plaintiffs’ expert opinions - reiterating the same flawed reasoning from her 2020 decision, disregarding changes to the Federal Rules of Evidence Company will promptly appeal to the District Court the erroneous aspects of the recommendation, which has no legal import until that appeal is resolved Recommendation only reinforces the Company’s overall litigation strategy

Company has prevailed in 16 of 17 ovarian cases tried in the last 11 years Company will reverse approximately $7 billion from amounts previously reserved for the bankruptcy resolution